ADAR and neoplasm: Using GC tissue samples and cell lines (AGS and HGC-27, together with their cisplatin-resistant variants), the authors investigated the correlation between ADAR1 and its downstream target, AZIN1, with EMT-related markers by several methods, including immunocytochemistry, western blotting, RNA interference (siRNA), and in vivo models of tumor growth (31).